Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
RAP-219
product2 mentionslast seen Oct 30, 2026
An investigational clinical-stage TARP gamma 8-specific AMPA receptor negative allosteric modulator being developed for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania.
Relationships 7
- Rapport Therapeutics, Inc.developsRAP-21999% confidence2 sources
- RAP-219applies tobipolar mania treatment96% confidence1 source
- RAP-219implementsTARP gamma 8-selective AMPA receptor negative allosteric modulation92% confidence1 source
- RAP-219applies tofocal onset seizures treatment90% confidence1 source
- RAP-219applies toprimary generalized tonic-clonic seizures treatment90% confidence1 source
- RAP-219applies todrug resistant focal onset seizures treatment90% confidence1 source
- RAP-219applies toacute bipolar mania treatment85% confidence1 source
Relationship
Rapport Therapeutics, Inc.developsRAP-219
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 30, 2026Rapport Therapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.02: Results of Operations and Financial Condition; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 3.02: Unregistered Sales of Equity Securities; Item 9.01: Financial Statements and Exhibits
to fund its ongoing and planned clinical trials advancing RAP-219
- filingSEC EDGAROct 20, 2026Rapport Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Rapport Therapeutics, Inc... a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines